Irisin Alleviates Inflammatory Injury in Diabetic Cardiomyopathy by Regulating NF-κB Pathway

ZHANG Chi , HUANG Jing, YANG Ping, LIU Xing, FAN Zhong-cai

Abstract

To investigate the protective effect of irisin in diabetic cardiomyopathy (DCM) and its mechanism.   Methods  A mouse model of DCM was established by high-fat diet combined with the injection of streptozotocin. The mice were assigned to a control group, a DCM group, a DCM+low-dose irisin group, a DCM+high-dose irisin group, and a DCM+pyrrolidine dithiocarbamate (PDTC) (nuclear factor [NF]-κB inhibitor) group. Then, the mice received irisin intervention for 3 weeks after successful modeling. Myocardial morphologic changes were observed by hematoxylin and eosin (HE) staining and Masson staining. The levels of serum creatine kinase (CK) and creatine kinase isoenzyme CK-MB were examined by automatic biochemical analyzer. H9c2 cells were divided into the control group, high glucose and high lipid (HG/HL) group, HG/HL+low-dose irisin group, HG/HL+high-dose irisin group, and HG/HL+PDTC group. CCK-8 assay was conducted to determine cell viability. The expression levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 in the myocardial tissue and the cells were determined by ELISA. In addition, nuclear translocation of NF-κB p65 protein and the protein expression level of NF-κB inhibitor protein α (IκBα) in the myocardial tissue and the cells were determined by Western blot.   Results  According to the results of animal experiment, low and high doses of irisin could alleviate the pathological injury and fibrosis of myocardial tissue to varying degrees. Irisin inhibited the levels of CK, CK-MB, and inflammatory factors, up-regulated IκB protein expression, and diminished NF-κB nuclear translocation. According to the results of cell experiment, low and high doses of irisin could enhance H9c2 cell viability to varying degrees, increase the level of intracellular IκB proteins, and inhibit NF-κB p65 nuclear translocation and inflammatory factor expression. The changes in these aspects in the DCM+low-dose irisin group and the DCM+high-dose irisin group were similar to those in the DCM+PDTC group.  Conclusion  Through inhibiting NF-κB p65 nuclear translocation, irisin may reduce the inflammatory response in the myocardial tissue of DCM mice and H9c2 cells of myocardial injury induced by high glucose and high fat, thereby exerting a protective effect on myocardium.

 

Keywords: Diabetic cardiomyopathy, Irisin, H9c2 cells, Mice, Inflammatory response, NF-κB nuclear translocation

 

Full Text:

PDF


References


JIA G， WHALEY-CONNELL A， SOWERS J R. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia，2018，61(1): 21–28. doi: 10.1007/s00125-017-4390-4.

FAN G H， ZHU T Y， HUANG J. FNDC5 promotes paclitaxel sensitivity of non-small cell lung cancers via inhibiting MDR1. Cell Signal，2020，72: 109665. doi: 10.1016/j.cellsig.2020.109665.

PAN J A， ZHANG H， YU Q， et al. Association of circulating irisin levels and the characteristics and prognosis of coronary artery disease. Am J Med Sci，2021，362(1): 63–71. doi: 10.1016/j.amjms.2021.02.020.

SHAO L， MENG D， YANG F， et al. Irisin-mediated protective effect on LPS-induced acute lung injury via suppressing inflammation and apoptosis of alveolar epithelial cells. Biochem Biophys Res Commun， 2017，487(2): 194–200. doi: 10.1016/j.bbrc.2017.04.020.

LING L， CHEN D， TONG Y， et al. Fibronectin type Ⅲ domain containing 5 attenuates NLRP3 inflammasome activation and phenotypic transformation of adventitial fibroblasts in spontaneously hypertensive rats. J Hypertens，2018，36(5): 1104–1114. doi: 10.1097/HJH. 0000000000001654.

LI X， JAMAL M， GUO P， et al. Irisin alleviates pulmonary epithelial barrier dysfunction in sepsis-induced acute lung injury via activation of AMPK/SIRT1 pathways. Biomed Pharmacother，2019，118: 109363. doi: 10.1016/j.biopha.2019.109363.

DENG J， ZHANG N， CHEN F， et al. Irisin ameliorates high glucose-induced cardiomyocytes injury via AMPK/mTOR signal pathway. Cell Biol Int，2020，44(11): 2315–2325. doi: 10.1002/cbin.11441.

DUAN H， MA B， MA X， et al. Anti-diabetic activity of recombinant irisin in STZ-induced insulin-deficient diabetic mice. Int J Biol Macromol，2016，84: 457–463. doi: 10.1016/j.ijbiomac.2015.12.049.

SONG R， ZHAO X， CAO R， et al. Irisin improves insulin resistance by inhibiting autophagy through the PI3K/Akt pathway in H9c2 cells. Gene， 2021，769: 145209. doi: 10.1016/j.gene.2020.145209.

PAOLILLO S， MARSICO F， PRASTARO M， et al. Diabetic cardiomyopathy: definition, diagnosis, andt herapeutic implications. Heart Fail Clin，2019，15(3): 341–347. doi: 10.1016/j.hfc.2019.02.003.

DUN S L， LYU R M， CHEN Y H， et al. Irisin-immunoreactivity in neural and non-neural cells of the rodent. Neuroscience，2013，240: 155–162. doi: 10.1016/j.neuroscience.2013.02.050.

WANG H， ZHAO Y T， ZHANG S， et al. Irisin plays a pivotal role to protect the heart against ischemia and reperfusion injury. J Cell Physiol， 2017，232(12): 3775–3785. doi: 10.1002/jcp.25857.

TAN Y， OUYANG H， XIAO X， et al. Irisin ameliorates septic cardiomyopathy via inhibiting DRP1-related mitochondrial fission and normalizing the JNK-LATS2 signaling pathway. Cell Stress Chaperones， 2019，24(3): 595–608. doi: 10.1007/s12192-019-00992-2.

ANASTASILAKIS A D， KOULAXIS D， KEFALA N， et al. Circulating irisin levels are lower in patients with either stable coronary artery disease (CAD) or myocardial infarction (MI) versus healthy controls, whereas follistatin and activin A levels are higher and can discriminate MI from CAD with similar to CK-MB accuracy. Metabolism，2017，73: 1–8. doi: 10. 1016/j.metabol.2017.05.002.

BASHAR S M， SAMIR El-SHERBEINY S M， BORAIE M Z. Correlation between the blood level of irisin and the severity of acute myocardial infarction in exercise-trained rats. J Basic Clin Physiol Pharmacol，2018， 30(1): 59–71. doi: 10.1515/jbcpp-2018-0090.

JIA G， HILL M A， SOWERS J R. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res，2018，122(4): 624–638. doi: 10.1161/CIRCRESAHA.117.311586.

MANILALL A， MOKOTEDI L， GUNTER S， et al. Inflammation-induced left ventricular fibrosis is partially mediated by tumor necrosis factor-α. Physiol Rep，2021，9(21): e15062. doi: 10.14814/phy2.15062.

LI Q， ZHANG M， ZHAO Y， et al. Irisin protects against LPS-stressed cardiac damaget hrough inhibiting inflammation, apoptosis, and pyroptosis. Shock，2021，56(6): 1009–1018. doi: 10.1097/SHK. 0000000000001775.

BARNABEI L， LAPLANTINE E， MBONGO W， et al. NF-κB: at the borders of autoimmunity and inflammation. Front Immunol，2021，12: 716469. doi: 10.3389/fimmu.2021.716469.

MULERO M C， HUXFORD T， GHOSH G. NF-κB, IκB, and IKK: integral components of immune system signaling. Adv Exp Med Biol， 2019，1172: 207–226. doi: 10.1007/978-981-13-9367-9_10.

FRATI G， SCHIRONE L， CHIMENTI I， et al. An overview of the inflammatory signalling mechanisms in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovasc Res，2017，113(4): 378–388. doi: 10.1093/cvr/cvx011.


Refbacks

  • There are currently no refbacks.